PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Injections, Intramuscular”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 937 records · Page 52Linked to original sources
PubMed1995

Comparative pharmacokinetics of 2 brands of cefuroxime following a single intramuscular injection.

The pharmacokinetic parameters (AUC0-8h, AUC0-infinity, Cmax, tmax, t1/2, Ke) of cefuroxime following a single intramuscular injection of 750 mg of a test product (Maxil, Hikma Pharmaceuticals, Amman, Jordan) were compared to those of a reference product (Zinacef, Glaxo, UK). The 2 products were administered according to a randomized 2-way crossover design to 26 healthy male volunteers. Cefuroxime plasma concentrations were determined using a rapid, sensitive and precise HPLC method with UV detection at 280 nm. The means of the ratios AUC0-infinity Maxil/AUC0-infinity Zinacef and Cmax Maxil/Cmax Zinacef were close to 1 and their 90% confidence intervals included 1. The mean pharmacokinetic parameters of the 2 products were not different and their 90% confidence intervals overlapped. The 2 products were not statistically different with respect to both rate and extent of absorption as demonstrated by statistical analysis on Cmax, tmax, AUC0-8h and AUC0-infinity. The 2 products were also similar regarding t1/2 and Ke. The ANOVA analysis showed no differences in the pharmacokinetic parameters of the 2 products in relation to treatment, sequence of product administration or the interaction term. Pharmacokinetic parameters of cefuroxime were comparable to reported values. We conclude that the 2 products of cefuroxime (Maxil and Zinacef) are bioequivalent.

Adult↗
PubMed1997

[Clostridium myonecrosis as a sequelae of intramuscular injections--description of 3 fatal outcomes].

In three fatal cases of clostridial myonecrosis, the following criteria were found: repeated intramuscular injections over several years with anti-inflammatory substances, delay in diagnosis in outpatient care, and following uncontrollable systemic septic complications, despite radical surgical treatment. Only early, aggressive surgical interventions can stop the rapid course of necrotizing soft-tissue infections.

Adult↗
PubMed2007

Intramuscular injection of islet neogenesis-associated protein peptide stimulates pancreatic islet neogenesis in healthy dogs.

OBJECTIVES: Diabetes is a serious health problem. It has been proposed that islet neogenesis from pancreatic progenitor cells may restore insulin secretion in diabetic mammals. Islet neogenesis- associated protein (INGAP) stimulates islet neogenesis; therefore, we hypothesized that it would stimulate islet neogenesis in dogs. METHODS: Forty nondiabetic beagle dogs were randomly divided into 4 groups. Group 1 received daily intramuscular injections of vehicle, whereas the other 3 groups received daily INGAP injections of 0.5, 1.5, or 10 mg/kg. After 30 days, pancreatic tissues were collected, and RNA and histological sections were analyzed. RESULTS: In dogs treated with 1.5 mg/kg INGAP, there was a significant (P < 0.001) increase in the percentage of insulin-positive cells (P < 0.001) and insulin gene expression. There was a trend to increased insulin-positive cells and gene expression with treatments of 0.5 and 10 mg/kg peptide. Protein gene product 9.5-positive cells were increased with treatment. CONCLUSIONS: These results indicate that INGAP stimulates cells in the pancreatic duct epithelium of healthy dogs (putative islet progenitor cells) to develop along a neuroendocrine pathway and form new islets in response to INGAP peptide. The INGAP might be an effective therapy for diabetes.

Animals↗
PubMedDate not supplied

[Pharmacokinetics and biological availability of diclofenac preparations following intramuscular injection of 75 mg and oral administration of 150 mg of active drug].

Four different formulations of diclofenac sodium, a widely used NSAID, were administered to eight healthy young volunteers in a cross-over study, according to a latin-square design. The subjects received either 75 mg as intramuscular injections or 150 mg as enteric-coated tablets. Following administration, blood samples were drawn and analysed for unchanged diclofenac, employing HPLC. 72.9% of the oral dose was absorbed with an average lag-time of 2.2 h. Peak plasma concentrations amounted to 2.9 micrograms/ml after 3.1 h, as compared to 2.15 micrograms/ml, 20-30 min following an intramuscular injection of 75 mg. Diclofenac sodium was excreted with an average half-life of 1.15 h. The bioavailability of the three i.m. injectable solutions, as calculated from the area under the curve (AUC), did not differ significantly. The results suggest that i.m. injectable diclofenac sodium provides fast drug liberation suitable for acute analgesic treatment, although the general risk of i.m. injections, as well as the very rare risk of protracted anaphylactic shocks, has to be taken into account. Despite the high variability of absorption, peak plasma concentrations and bioavailability, the enteric-coated tablets may be favourable in chronic antiinflammatory therapy.

Administration, Oral↗
PubMed1997

Intramuscular injection of expression plasmid DNA is an effective means of long-term systemic delivery of interleukin-5.

It has been demonstrated that intramuscularly injected expression plasmid DNA is taken up by myofibers and subsequently expresses exogenous genes. In the present study, we assessed intramuscular DNA injection as a means of systemically delivering interleukin-5 (IL-5). We constructed an IL-5 expression plasmid, pCAGGS-IL-5, containing murine IL-5 cDNA under the control of the CAG promoter. The soleus muscle of mice was pretreated with bupivacaine. Two days later, mice were injected with pCAGGS-IL-5 or a control pCAGGS plasmid DNA at the same site. At 2 weeks after DNA injection, eosinophils had increased from 2-3% to 8-29% of peripheral white blood cells in 9 of 10 mice injected with pCAGGS-IL-5, while eosinophils never exceeded 3% in control mice injected with pCAGGS. IL-5 mRNA was present in the muscle area injected with pCAGGS-IL-5. IL-5 was also detectable by ELISA in the sera of most mice injected with pCAGGS-IL-5, but in none of the control mice. These results demonstrate that intramuscular plasmid injection serves as a useful method of systemically delivering cytokines by combining the strong CAG promoter and bupivacaine pretreatment.

Animals↗
PubMed1999

Intramuscular injection of plasmid DNA encoding cottontail rabbit papillomavirus E1, E2, E6 and E7 induces T cell-mediated but not humoral immune responses in rabbits.

To test the efficacy of genetic vaccination against papillomavirus infection, plasmid DNA encoding cottontail rabbit papillomavirus (CRPV) E1, E2, E6, E7 or without insert were intramuscularly injected into five groups of rabbits. Peripheral blood mononuclear cells (PBMCs) showed specific proliferation upon in vitro stimulation with E1, E2, E6 or E7 proteins in a majority of vaccinated rabbits but Western blot analysis did not detect antibodies specific for these viral proteins in rabbit serum. All rabbits grew papillomas after virus challenge and none of the rabbits showed systemic papilloma regression. These observations showed that intramuscular injection of plasmid DNA encoding CRPV E1, E2, E6 or E7 induced CD4+ T cell-mediated but not humoral immune responses, and did not result in the protection of rabbits from virus infection.

Animals↗
PubMed1980

Multiple intramuscular injections: a major source of variability in analgesic response to meperidine.

Meperidine (ethidine) blood concentrations following multiple intramuscular injections (100 mg) over 2 days were determined in 10 female patients undergoing elective abdominal hysterectomies or cholecystectomies. Pain was estimated by subjective bioassay and the relationship between concentration and effect determined. The blood concentration-effect curve was steep with the range from no analgesia to complete analgesia being 0.35--0.45 microgram/ml on day 1 and 0.4--0.5 microgram/ml on day 2. The mean (+/- S.D.) minimum analgesic blood concentration was 0.5 +/- 0.1 microgram/ml (n = 32). Pain control was poor during the first 4-h dosing interval. The first injection post-surgery was also found to be the least representative of all subsequent injections. Blood concentrations fluctuated in phase with dosing interval, but were highly variable. Intra- and inter-patient peak concentrations varied by 2- and 5-fold and times taken to reach the peaks by 3- and 7-fold, respectively. Hence, meperidine blood concentrations were in excess of the minimum analgesic concentration for only about 35% of each of each 4-h dosing interval. Peak concentrations were not consistently correlated with body weight or lean tissue mass. Variable pain control following intermittent intramuscular meperidine injections was shown to be due to inadequate, fluctuating and unpredictable blood concentrations.

Adult↗
PubMed1998

[Intramuscular injections of PGE1 in patients with severe claudication].

BACKGROUND: In this pilot study we selected 12 patients with short range claudication and treated, after informed consent, 6 patients (mean age 63 +/- 5; range 55-65) with severe claudication (walking distance < 100 m). Selection criteria were patent common and deep femoral artery, occluded superficial femoral artery with patent popliteal artery, with posterior tibial Doppler pressure > 50 mmHg and anterior tibial > 40 mmHg. METHODS: Patients were evaluated with a treadmill test performed to their walking limit. PGE1 was used by intramuscular injections (for a total of 80 micrograms, divided in 4 injections). The injections were about 2 cm deep in the posterior calf muscles. An exercise program was associated. Patients were required to walk 20 minutes just after the injections and to follow an exercise program (walking slowly at least 30 minutes, 3 times daily, in the following 4 weeks). RESULTS: Both the PGE1 group and a comparable control group (12 patients mean age 62 +/- 4; range 56-65) were treated with ASA and pentoxyfillin (400 mg t.i.d.). In the PGE1 group the average total walking distance at inclusion was 25 +/- 16 (range 0-52); it increased to 113 +/- 55 (range 50-289) (after 1 week) and to 117 +/- 27 (range 30-1020) at 4 weeks. No important changes were observed in the control group (54 +/- 6 m at inclusion, 58 +/- 8 after one week and 63 +/- 7 after 4 weeks). There were no important side effects. One patient experienced important injection pain which disappeared in a few hours. No significant changes in tibial pressures were observed. CONCLUSIONS: Intramuscular injection of PGE1 may be an interesting treatment option in patients with severe intermittent claudication but these preliminary findings should be verified in larger randomised studies.

Alprostadil↗
PubMed1981

Further studies of the effects of intravenous infusion or intramuscular injection of gonadotropin-releasing hormone during childhood and adolescence.

To provide data on the readily releasable pools of pituitary gonadotropins and to compare routes of administration, gonadotropin-releasing hormone (Gn-RH, 100 micrograms) was administered to 135 endocrinologically normal children and adolescents by continuous intravenous 3-hour infusion or by acute intramuscular injection. The Gn-RH infusion resulted in a significant four- and sevenfold increase in serum luteinizing hormone (LH) values in prepubertal subjects and pubertal males, respectively. A 14-fold increment, biphasic in appearance, occurred in pubertal females. Gn-RH-induced serum follicle-stimulating hormone (FSH) increases were greater in females than in males. Following intramuscular injection of Gn-RH, a monophasic increment of serum LH and FSH occurred. LH rises were greater in pubertal than in prepubertal children and greater in females than in males. FSH increments were greater in females than in males, prepubertal being slightly greater than pubertal. Urinary gonadotropin excretion mirrored the changes in the serum samples. These results in the largest reported group of normal children generally confirm those of previous reports except for the greater Gn-RH-evoked releasable LH in pubertal females than in males.

Adolescent↗
PubMed2006

Correction of anemia in uremic rats by intramuscular injection of lentivirus carrying an erythropoietin gene.

BACKGROUND: Anemia is an inevitable consequence of chronic renal failure. Gene therapy using lentiviral vector (LV) would be an effective tool to treat anemia associated with renal failure. METHODS: A LV carrying the erythropoietin (EPO) cDNA was administered to skeletal muscle of partially nephrectomized rats, which is a model of uremia. The red blood cell production and serum EPO levels were temporally monitored in these rats. Polymerase chain reaction assays were done to validate the presence of the LV in the experimental rats. RESULTS: After a single intramuscular injection of LV at a dose of 55 microg p24 Gag antigen (approximately 5 x 10(7) transducing units), blood hematocrit (Hct) levels increased and peaked at 3 weeks (47.8 +/- 4.2%, p < 0.01, n = 8) with the levels being maintained for at least 20 weeks (duration of study; 44.9 +/- 3.3%, p < 0.01, n = 3). The control rats receiving LV expressing lacZ had Hct levels of 36.9 +/- 4.1% (n = 8) at 3 weeks and 33.1 +/- 3.7% (n = 4) at 20 weeks, respectively. The serum EPO levels in the rats injected with the LV expression EPO significantly increased (p < 0.01) to 156.3 +/- 3.0 mU/ml compared to the control rats (63.9 +/- 1.7 mU/ml). Polymerase chain reaction analysis of the isolated genomic DNA from the LV-injected rats showed specific positive detection of the LV in only the skeletal muscle tissue at the site of injection, whereas the other tissues, including the liver, spleen, and kidney, were negative. CONCLUSIONS: This study demonstrates that intramuscular injection of LV can produce highly efficient and sustained EPO secretion in uremic rats, and suggests that this approach could be an effective tool to deliver secretable proteins at therapeutic levels in various animal disease models.

Anemia↗
PubMed1994

How safe are intramuscular injections?

The authors present an overview of adverse effects associated with intramuscular injections and factors contributing to these effects. Guidelines for both general and critical care patients are proposed after evaluating available research and case history literature. Recommendations include re-evaluating the appropriateness of the intramuscular route for administration of drugs to critical care patients. Avoidance of this route for most critically ill patients is suggested.

Critical Care↗
PubMed1991

Treatment of polymyalgia rheumatica with intramuscular injections of depot methylprednisolone.

Although the treatment of patients with polymyalgia rheumatica by corticosteroids given by mouth is effective, it is often accompanied by multiple side effects. Various studies have shown that the steroid related complications are proportional to the cumulative dose of steroids administered. In a prospective study of 16 patients with polymyalgia rheumatica the effects of regular intramuscular injections of methylprednisolone over 12 months were evaluated. Remission of disease was achieved with injections of 120 mg of methylprednisolone every three weeks for 12 weeks. Subsequent disease remission was maintained by monthly injections of methylprednisolone on a reducing schedule of dose. The treatment was efficacious, safe, well tolerated over one year, and showed no suppression of the hypothalamic pituitary adrenal axis at 12 weeks after initiation of treatment. Such a mode of steroid treatment results in a considerably lower cumulative steroid dose than with conventional doses of prednisolone given by mouth. These results will be further evaluated in a controlled trial using intramuscular injections of methylprednisolone and prednisolone given by mouth for the treatment of polymyalgia rheumatica.

Delayed-Action Preparations↗
PubMed2003

Intramuscular injections of male pheromone 5 alpha-androstenol change the secretory ovarian function in gilts during sexual maturation.

In addition to the standard olfactory pathway typical for signaling pheromones, the existence of a humoral pathway for the priming action of pheromones has been earlier postulated. In this study in vivo experiment was performed to establish whether intramuscular injections of boar pheromone, 5 alpha-androstenol (5 alpha-androst-16-en-3-ol), might change the development and secretory function of the ovarian follicles during sexual maturation of gilts. Gilts from groups I (n=15) and II (n=13) received androstenol (10 microg/gilt/injection; i.m.) three times a week from day 192 to 234 of age. Similar, control gilts (group C; n=13) received saline. Additionally, the nasal cavity of animals from group II was irrigated with zinc sulfate solution to depress olfactory function. The reproductive organs and follicular fluid were collected on day 240 of age. There were no significant differences among groups concerning the weight of the ovary and uterus, the length of the uterine horns and intensity of cytochrome P450(scc) and P450(arom) immunoexpression. However, gilts treated with boar pheromone had a higher (p<0.01) total number of follicles > 3 mm in diameter and a lower index of atresia. In addition, androstenol-treated animals were characterized by higher concentrations of progesterone (the 1-3 mm and 3-6 mm follicles; p<0.01 and 0.001, respectively) and estradiol (follicles 3-6 mm; p<0.001) than those of controls. The results of the present study demonstrate that intramuscular injections of androstenol stimulate the development and secretory function of the ovarian follicles in gilts during sexual maturation. They also support the hypothesis that androstenol, as a priming boar pheromone, may influence reproductive processes in female pigs acting as a chemical signal via humoral pathway.

Androstenols↗
PubMed1981

Lincomycin serum and saliva concentrations after intramuscular injection of high doses.

Serum and saliva levels of lincomycin were determined in 15 normal adult male volunteers after a single intramuscular injection of 600, 1000, or 1500 mg lincomycin in a three-way crossover study. The area under the serum concentration-time curve did not increase in proportion to the increase in dose. The increase in concentration of lincomycin in saliva was greater than expected for the increase in dose. There were not significant differences in elimination half-life between doses. These results suggest that the apparent clearance of lincomycin increases with increasing dose possibly because of a decrease in serum protein binding of lincomycin at high serum concentrations.

Adult↗
PubMed1980

Effect of an intramuscular injection of human leukocyte interferon on blood leukocyte counts and proportions of lymphocytes forming E, EA and EAC rosettes.

Following an intramuscular injection of human leukocyte interferon blood leukocyte counts decreased in most patients as tested 24 h after the injection. This decrease comprised lymphocytes, monocytes and granulocytes, 24 h after interferon injection, the proportion of lymphocytes forming E rosettes was incresed in most patients, whereas the proportion of lymphocytes forming EA and EAC rosettes was not significantly changed.

Adolescent↗
PubMed1976

Peripheral nerve injuries from intramuscular injection of drugs.

17 patients who were treated at the University of Nigeria Teaching Hospital for peripheral nerve paralysis resulting from intramuscular injection of drugs are analyzed. Ten of them were below the age of 5 years. Sciatic nerve was affected in 16 patients and only one patient had median nerve paralysis. Penicillin, ampicillin, tetracycline, paraldehyde and optalgin were some of the offending drugs. The prognosis was poor as only three patients achieved a partial recovery of function in the paralyzed nerves. With determination and public education, this iatrogenic tragedy could be eradicated.

Adolescent↗
PubMed1993

Intramuscular injection as a provoking factor for paralysis in acute poliomyelitis. A case control study.

In order to identify the role of intramuscular injection (IM) as a provoking factor for poliomyelitis, a case control study as done at the Institute of Child Health, Madras from May 1988 to May 1989. The case was defined as acute poliomyelitis if he had acute asymmetric flaccid paralysis of lower motor neurone type without objective sensory disturbance following a short episode of fever. Controls were taken from children attending outpatient department for fever. Two controls matched for aged and sex were recruited for each case. Recruitment, data collection and clinical examination were done by a single pediatrician. IM injection received within 30 days prior to onset of paralysis or illness was considered to be the risk factor. The total number of cases and controls recruited were 257 and 515, respectively. Among cases, 172 (66.9%) out of 257 and among controls 252 (48.9%) out of 515, received IM injection within one month earlier to onset of paralysis or illness. The overall risk of paralysis, estimated for IM injection, was increased [odds ratio (OR) 2.1 (95% CI, 1.5-3.0)]. The maximum risk for paralysis was observed to be 2 weeks preceding the illness; the ORs for < 7 days was 2.2 (95% CI, 1.6-3.2) and for 7-13 days 3.2 (95% CI, 1.8 to 5.8). The risk of paralysis associated with IM injection was similar for unimmunized and immunized cases (OR 2.4 and 2.2). Multiple injections were not associated with a higher risk of developing paralysis.(ABSTRACT TRUNCATED AT 250 WORDS)

Acute Disease↗